title: [Advances in the study of structural modifications of multi-target anticancer drug sorafenib].
abstract: Sorafenib, the first oral multikinase inhibitor, can inhibit several kinases involved in tumor proliferation and angiogenesis including Raf, VEGFR, PDGFR, kit and so on. Due to the advantages of multi-mechanisms, broad-spectrum anticancer potency, and well-tolerated results in combination trials, more and more researchers have focused on the optimization of sorafenib in order to develop novel multi-targeted anticancer drugs. The present paper reviews the development of modification of sorafenib in recent years from two aspects: bio-isosterism and scaffold hopping. The structure-activity relationship (SAR) of these compounds is also summarized.
authors.affiliation: School of Pharmaceutical Sciences, Shandong University Jinan 250012, China.
authors.forename: Jian-Wen
authors.initials: JW
authors.lastname: Yao
authors.forename: Wei
authors.initials: W
authors.lastname: Sun
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: Wen-Fang
authors.initials: WF
authors.lastname: Xu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry; D045744:Cell Line, Tumor; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry; D010671:Phenylurea Compounds / Q000138:chemical synthesis* / Q000737:chemistry; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry; D000077157:Sorafenib; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib